For: | Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A. Valproic acid and nonalcoholic fatty liver disease: A possible association? World J Hepatol 2015; 7(9): 1251-1257 [PMID: 26019740 DOI: 10.4254/wjh.v7.i9.1251] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v7/i9/1251.htm |
Number | Citing Articles |
1 |
Bernard Fromenty. Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis. Liver Research 2019; 3(3-4): 157 doi: 10.1016/j.livres.2019.06.001
|
2 |
Lydia James George, Preeti Singh, Satinder Aneja, Ritu Singh, RS Solanki, Anju Seth. Insulin Resistance in children on Sodium Valproate – A hospital based cross-sectional study in Indian children. Tropical Doctor 2023; 53(1): 91 doi: 10.1177/00494755221134141
|
3 |
Samantha Christine Sernoskie, Alison Jee, Jack Paul Uetrecht, Eric Barker. The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions. Pharmacological Reviews 2021; 73(3): 861 doi: 10.1124/pharmrev.120.000090
|
4 |
Renchao Dong, Xiaobo Yang, Changyuan Wang, Kexin Liu, Zhihao Liu, Xiaodong Ma, Huijun Sun, Xiaokui Huo, Ting Fu, Qiang Meng. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor. Phytomedicine 2019; 53: 134 doi: 10.1016/j.phymed.2018.09.006
|
5 |
Polina Soluyanova, Marta del Pozo, Erika Moro-Castaño, Ana V. Marco-Hernández, José V. Castell, Ramiro Jover. A microRNA signature for valproate-induced steatosis in human hepatocytes and its application to predict fatty liver in paediatric epileptic patients on valproate therapy. Toxicology 2024; 509: 153974 doi: 10.1016/j.tox.2024.153974
|
6 |
AM Hegazy, AS Abdel-Azeem, HM Zeidan, KS Ibrahim, EM El Sayed. Hypolipidemic and hepatoprotective activities of rosemary and thyme in gentamicin-treated rats. Human & Experimental Toxicology 2018; 37(4): 420 doi: 10.1177/0960327117710534
|
7 |
Marta Moreno-Torres, Carla Guzmán, Petar D. Petrov, Ramiro Jover. Valproate and Short-Chain Fatty Acids Activate Transcription of the Human Vitamin D Receptor Gene through a Proximal GC-Rich DNA Region Containing Two Putative Sp1 Binding Sites. Nutrients 2022; 14(13): 2673 doi: 10.3390/nu14132673
|
8 |
A. A. Verhaegen, L. F. Van Gaal. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. Journal of Endocrinological Investigation 2017; 40(11): 1165 doi: 10.1007/s40618-017-0719-6
|
9 |
Hong-Li Guo, Xia Jing, Jie-Yu Sun, Ya-hui Hu, Ze-Jun Xu, Ming-Ming Ni, Feng Chen, Xiao-Peng Lu, Jin-Chun Qiu, Tengfei Wang. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. Current Pharmaceutical Design 2019; 25(3): 343 doi: 10.2174/1381612825666190329145428
|
10 |
Entsar A. Nazmy, Omar A. El-Khouly, Hoda Atef, Eman Said. Sulforaphane protects against sodium valproate–induced acute liver injury. Canadian Journal of Physiology and Pharmacology 2017; 95(4): 420 doi: 10.1139/cjpp-2016-0447
|
11 |
Aleksei Rakitin, Sulev Kõks, Sulev Haldre. Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine. Seizure 2016; 38: 11 doi: 10.1016/j.seizure.2016.03.008
|
12 |
Durmuş HATİPOĞLU, Mehmet ÖZSAN, Hasan Hüseyin DÖNMEZ, Nurcan DÖNMEZ. Hepatoprotective effects of Nigella Sativa oil against acrylamide-induced liver injury in rats. Ankara Üniversitesi Veteriner Fakültesi Dergisi 2023; 70(4): 419 doi: 10.33988/auvfd.1096306
|
13 |
Ming-Lu Wang, Yu-Jia Zhang, Da-Long He, Tong Li, Ming-Ming Zhao, Li-Mei Zhao. Inhibition of PLA2G4A attenuated valproic acid- induced lysosomal membrane permeabilization and restored impaired autophagic flux: Implications for hepatotoxicity. Biochemical Pharmacology 2024; 227: 116438 doi: 10.1016/j.bcp.2024.116438
|
14 |
David Grünig, Leonora Szabo, Martina Marbet, Stephan Krähenbühl. Valproic acid affects fatty acid and triglyceride metabolism in HepaRG cells exposed to fatty acids by different mechanisms. Biochemical Pharmacology 2020; 177: 113860 doi: 10.1016/j.bcp.2020.113860
|
15 |
Xupeng Bai, Weipeng Hong, Peiheng Cai, Yibei Chen, Chuncao Xu, Di Cao, Weibang Yu, Zhongxiang Zhao, Min Huang, Jing Jin. Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis. Toxicology and Applied Pharmacology 2017; 324: 12 doi: 10.1016/j.taap.2017.03.022
|
16 |
Alex Claveria-Cabello, Leticia Colyn, Maria Arechederra, Jesus M. Urman, Carmen Berasain, Matias A. Avila, Maite G. Fernandez-Barrena. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?. Cells 2020; 9(10): 2321 doi: 10.3390/cells9102321
|
17 |
Cucnhat P. Walker, Subrata Deb. Rhabdomyolysis and Hepatotoxicity From Valproic Acid: Case Reports. Journal of Pharmacy Practice 2021; 34(4): 648 doi: 10.1177/0897190019882880
|
18 |
Maria Zhelyazkova-Savova, Koraliya Todorova-Nenova, Silviya Gancheva, Desislava Karadjova. Evaluation of potential drug-drug interactions in psychiatric patients: a pilot study. Scripta Scientifica Medica 2018; 50(3): 13 doi: 10.14748/ssm.v50i3.5484
|
19 |
Renata Alfani, Edoardo Vassallo, Anna Giulia De Anseris, Lucia Nazzaro, Ida D'Acunzo, Carolina Porfito, Claudia Mandato, Pietro Vajro. Pediatric Fatty Liver and Obesity: Not Always Just a Matter of Non-Alcoholic Fatty Liver Disease. Children 2018; 5(12): 169 doi: 10.3390/children5120169
|
20 |
Hui Hua Chang, Yuan-Shuo Hsueh, Yung Wen Cheng, Huai-Hsuan Tseng. A Longitudinal Study of the Association between the LEPR Polymorphism and Treatment Response in Patients with Bipolar Disorder. International Journal of Molecular Sciences 2022; 23(17): 9635 doi: 10.3390/ijms23179635
|
21 |
Jordi Valls-Margarit, Janet Piñero, Barbara Füzi, Natacha Cerisier, Olivier Taboureau, Laura I. Furlong. Assessing network-based methods in the context of system toxicology. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1225697
|
22 |
Xupeng Bai, Chuncao Xu, Dingsheng Wen, Yibei Chen, Hongliang Li, Xueding Wang, Liemin Zhou, Min Huang, Jing Jin. Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients. Psychopharmacology 2018; 235(9): 2665 doi: 10.1007/s00213-018-4960-2
|
23 |
James E. Klaunig, Xilin Li, Zemin Wang. Role of xenobiotics in the induction and progression of fatty liver disease. Toxicology Research 2018; 7(4): 664 doi: 10.1039/c7tx00326a
|
24 |
Aleksei Rakitin. Does Valproic Acid Have Potential in the Treatment of Diabetes Mellitus?. Frontiers in Endocrinology 2017; 8 doi: 10.3389/fendo.2017.00147
|
25 |
Abdalla M. El-Mowafy, Mohamed M. Katary, Chelsey Pye, Ahmed S. Ibrahim, Ahmed A. Elmarakby. Novel molecular triggers underlie valproate-induced liver injury and its alleviation by the omega-3 fatty acid DHA: role of inflammation and apoptosis. Heliyon 2016; 2(7): e00130 doi: 10.1016/j.heliyon.2016.e00130
|
26 |
Silvia Sookoian, Carlos J. Pirola. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. Clinical and Molecular Hepatology 2020; 26(4): 461 doi: 10.3350/cmh.2020.0136
|
27 |
Gabriel M Ronen, Ian Janssen. Patterns of daily activity among young people with epilepsy. Developmental Medicine & Child Neurology 2019; 61(12): 1386 doi: 10.1111/dmcn.14223
|
28 |
Kai-jing Zhao, Yang Chen, Shi-jin Hong, Yi-ting Yang, Jiong Xu, Han-yu Yang, Liang Zhu, Ming Liu, Qiu-shi Xie, Xian-ge Tang, Ting-ting Yang, Ya-qian Zhou, Li Liu, Xiao-dong Liu. Characteristics of β-oxidative and reductive metabolism on the acyl side chain of cinnamic acid and its analogues in rats. Acta Pharmacologica Sinica 2019; 40(8): 1106 doi: 10.1038/s41401-019-0218-8
|
29 |
Laura Giuseppina Di Pasqua, Marta Cagna, Clarissa Berardo, Mariapia Vairetti, Andrea Ferrigno. Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. Biomedicines 2022; 10(1): 194 doi: 10.3390/biomedicines10010194
|
30 |
Jakub Krzysztof Rogalski, Aleksandra Subdys, Oliwia Ewa Gawlik-Kotelnicka. The development of the Metabolic-associated Fatty Liver Disease during pharmacotherapy of mental disorders - a review. Current Problems of Psychiatry 2022; 23(3): 128 doi: 10.2478/cpp-2022-0013
|
31 |
Fernando Bessone, Melisa Dirchwolf, María Agustina Rodil, María Valeria Razori, Marcelo G. Roma. Review article: drug‐induced liver injury in the context of nonalcoholic fatty liver disease – a physiopathological and clinical integrated view. Alimentary Pharmacology & Therapeutics 2018; 48(9): 892 doi: 10.1111/apt.14952
|
32 |
R. Jover, P. Soluyanova, E. Moro-Castaño, M. Moreno-Torres, A.V. Marco-Hernández, M. Tomas-Vila, J.V. Castell. SOC-V-11 New serum miRNA biomarkers to predict liver steatosis by valproic acid in paediatric epileptic patients. Toxicology Letters 2022; 368: S68 doi: 10.1016/j.toxlet.2022.07.200
|
33 |
Ophelia Godin, Marion Leboyer, Raoul Belzeaux, Frank Bellivier, Joséphine Loftus, Philippe Courtet, Caroline Dubertret, Sebastien Gard, Chantal Henry, Pierre‐Michel Llorca, Raymund Schwan, Christine Passerieux, Mircea Polosan, Ludovic Samalin, Emilie Olié, Bruno Etain. Non‐alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE‐BD cohort. Acta Psychiatrica Scandinavica 2021; 143(1): 82 doi: 10.1111/acps.13239
|
34 |
Carmine Merola, Giulia Caioni, Annamaria Cimini, Monia Perugini, Elisabetta Benedetti. Sodium valproate exposure influences the expression of pparg in the zebrafish model. Birth Defects Research 2023; 115(6): 658 doi: 10.1002/bdr2.2159
|
35 |
Neeti Agarwal, Dinakar Iyer, Chiara Gabbi, Pradip Saha, Sanjeet G. Patel, Qianxing Mo, Benny Chang, Biman Goswami, Ulrich Schubert, Jeffrey B. Kopp, Dorothy E. Lewis, Ashok Balasubramanyam. HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRα and PPARα dysregulation: implications for HIV-specific pathogenesis of NAFLD. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-13835-w
|
36 |
Sabbir Khan, Sandeep Kumar, Gopabandhu Jena. Valproic acid reduces insulin-resistance, fat deposition and FOXO1-mediated gluconeogenesis in type-2 diabetic rat. Biochimie 2016; 125: 42 doi: 10.1016/j.biochi.2016.02.014
|
37 |
Sandra Torres, Anna Baulies, Naroa Insausti-Urkia, Cristina Alarcón-Vila, Raquel Fucho, Estel Solsona-Vilarrasa, Susana Núñez, David Robles, Vicent Ribas, Leslie Wakefield, Markus Grompe, M. Isabel Lucena, Raul J. Andrade, Sanda Win, Tin A. Aung, Neil Kaplowitz, Carmen García-Ruiz, Jose C. Fernández-Checa. Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. Gastroenterology 2019; 157(2): 552 doi: 10.1053/j.gastro.2019.04.023
|
38 |
Ann A. Verhaegen, Luc F. Van Gaal. Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function—Mechanisms and Possible Therapeutic or Preventive Measures: an Update. Current Obesity Reports 2021; 10(1): 1 doi: 10.1007/s13679-020-00419-5
|
39 |
Wenyi Deng, Wenjing Fan, Tingting Tang, Hengquan Wan, Simin Zhao, Yao Tan, Kwabena Agyare Oware, Jieqiong Tan, Jiequn Li, Shunlin Qu, Ramoji Kosuru. Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. Oxidative Medicine and Cellular Longevity 2022; 2022: 1 doi: 10.1155/2022/3589525
|
40 |
Yi-Wen Li, Chung-Hsing Wang, Chao-Jung Chen, Charles C. N. Wang, Cheng-Li Lin, Wai-Kok Cheng, Hsin-Yi Shen, Yun-Ping Lim. Effects of antiepileptic drugs on lipogenic gene regulation and hyperlipidemia risk in Taiwan: a nationwide population-based cohort study and supporting in vitro studies. Archives of Toxicology 2018; 92(9): 2829 doi: 10.1007/s00204-018-2263-3
|
41 |
Shansen Xu, Yanan Chen, Yiyi Ma, Ting Liu, Mingming Zhao, Zhanyou Wang, Limei Zhao. Lipidomic Profiling Reveals Disruption of Lipid Metabolism in Valproic Acid-Induced Hepatotoxicity. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00819
|
42 |
Dhirendra Singh, Sumeet Gupta, Inderjeet Verma, Mohamed A. Morsy, Anroop B. Nair, Al-Shaimaa F. Ahmed. Hidden pharmacological activities of valproic acid: A new insight. Biomedicine & Pharmacotherapy 2021; 142: 112021 doi: 10.1016/j.biopha.2021.112021
|